JW Therapeutics Wins China’s Second CAR-T Approval
Reimbursement A Challenge
Executive Summary
The approval of China's second CAR-T therapy has come amid reimbursement challenges, despite the pricing of its direct competitor being much lower than in the US. Chinese developers are pinning their hopes on rapid domestic market expansion via commercial insurance tie-ups as other CAR-Ts move through local development.
You may also be interested in...
First Pre-Revenue Biotech IPO Rejection By 'China’s Nasdaq'
The STAR Market of the Shanghai Stock Exchange has called a halt to the potentially third-largest biotech IPO this year in an apparent deterrent to the in-licensing model.
Asia Deal Watch: Beximco Broadens Offerings, Capabilities With Sanofi Bangladesh Buy
Plus deals involving Biosplice/Haisco, SciClone/Tarveda, Everest/Sinovent/SinoMab, Kyowa Kirin/AM-Pharma, Sandoz/Bio-Thera, Dr. Reddy’s/Citius, Jiangsu Hengrui/Mabworks, GeneQuantum/BrightGene, Innovent/GenFleet and Takeda/Mirum.
China's Medtech Regulatory Update Does Not Go Far Enough For Overseas Innovators
Foreign medical device innovators accessing the Chinese market remain at a disadvantage to local companies, even after the recent regulatory pathway revision.